Advancing pancreatic cancer research and therapeutics: the transformative role of organoid technology

Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324–338 (2015).
Google Scholar
Moreira, L. et al. Pancreas 3D organoids: current and future aspects as a research platform for personalized medicine in pancreatic cancer. Cell Mol. Gastroenterol. Hepatol. 5, 289–298 (2018).
Google Scholar
Marsee, A. et al. Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell 28, 816–832 (2021).
Google Scholar
Huch, M. et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J. 32, 2708–2721 (2013).
Google Scholar
Li, X. et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat. Med. 20, 769–777 (2014).
Google Scholar
Githens, S., Holmquist, D. R., Whelan, J. F. & Ruby, J. R. Ducts of the rat pancreas in a agarose matrix culture. Vitro 16, 797–808 (1980).
Google Scholar
Pylayeva-Gupta, Y., Lee, K. E. & Bar-Sagi, D. Microdissection and culture of murine pancreatic ductal epithelial cells. Methods Mol. Biol. 980, 267–279 (2013).
Google Scholar
Jin, L. et al. Colony-forming cells in the adult mouse pancreas are expandable in Matrigel and form endocrine/acinar colonies in laminin hydrogel. Proc. Natl Acad. Sci. USA 110, 3907–3912 (2013).
Google Scholar
Reichert, M. et al. Isolation, culture and genetic manipulation of mouse pancreatic ductal cells. Nat. Protoc. 8, 1354–1365 (2013).
Google Scholar
Jensen, C. & Teng, Y. Is it time to start transitioning from 2D to 3D cell culture? Front. Mol. Biosci. 7, 33 (2020).
Google Scholar
Piroli, M. E., Blanchette, J. O. & Jabbarzadeh, E. Polarity as a physiological modulator of cell function. Front. Biosci. (Landmark Ed.) 24, 451–462 (2019).
Google Scholar
Longati, P. et al. 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer 13, 95 (2013).
Google Scholar
Raghavan, S. et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 184, 6119–6137.e26 (2021).
Google Scholar
Hwang, W. L. et al. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nat. Genet. 54, 1178–1191 (2022).
Google Scholar
Zhou, X. et al. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Nat. Cancer 4, 1362–1381 (2023).
Google Scholar
Tiriac, H., Plenker, D., Baker, L. A. & Tuveson, D. A. Organoid models for translational pancreatic cancer research. Curr. Opin. Genet. Dev. 54, 7–11 (2019).
Google Scholar
Malinova, A., Veghini, L., Real, F. X. & Corbo, V. Cell lineage infidelity in PDAC progression and therapy resistance. Front. Cell Dev. Biol. 9, 795251 (2021).
Google Scholar
LeSavage, B. L. et al. Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids. Nat. Mater. 23, 1138–1149 (2024).
Rice, A. J. et al. Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis 6, e352 (2017).
Google Scholar
Roe, J.-S. et al. Enhancer reprogramming promotes pancreatic cancer metastasis. Cell 170, 875–888.e20 (2017).
Google Scholar
Kim, H.-R. et al. EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer. NAR Cancer 3, zcab023 (2021).
Google Scholar
Xu, J. et al. Engrailed-1 promotes pancreatic cancer metastasis. Adv. Sci. (Weinh.) 11, e2308537 (2024).
Google Scholar
Maitra, A. & Hruban, R. H. Pancreatic cancer. Annu. Rev. Pathol. 3, 157–188 (2008).
Google Scholar
Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114–1117 (2010).
Google Scholar
Tiriac, H. et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 8, 1112–1129 (2018).
Google Scholar
Hwang, C.-I., Boj, S. F., Clevers, H. & Tuveson, D. A. Preclinical models of pancreatic ductal adenocarcinoma. J. Pathol. 238, 197–204 (2016).
Google Scholar
Shi, X. et al. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Nat. Commun. 13, 2169 (2022).
Google Scholar
Wang, S. et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct. Target Ther. 6, 249 (2021).
Google Scholar
Yoo, H.-B. et al. A TEAD2-driven endothelial-like program shapes basal-like differentiation and metastasis of pancreatic cancer. Gastroenterology 165, 133–148.e17 (2023).
Google Scholar
Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).
Google Scholar
Wang, S. S. et al. Whole-genome bisulfite sequencing identifies stage- and subtype-specific DNA methylation signatures in pancreatic cancer. iScience 27, 109414 (2024).
Google Scholar
Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).
Google Scholar
Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).
Google Scholar
Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457–1461 (2009).
Google Scholar
He, M., Henderson, M., Muth, S., Murphy, A. & Zheng, L. Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma. Ann. Pancreat Cancer 3 (2020).
Grossman, J. E. et al. Organoid sensitivity correlates with therapeutic response in patients with pancreatic cancer. Clin. Cancer Res. 28, 708–718 (2022).
Google Scholar
Demyan, L. et al. Pancreatic cancer patient-derived organoids can predict response to neoadjuvant chemotherapy. Ann. Surg. 276, 450–462 (2022).
Google Scholar
Boilève, A. et al. Organoids for functional precision medicine in advanced pancreatic cancer. Gastroenterology 167, 961–976.e13 (2024).
Driehuis, E. et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc. Natl Acad. Sci. USA 116, 26580–26590 (2019).
Google Scholar
Hirt, C. K. et al. Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment. Cell Genomics 2, 100095 (2022).
Google Scholar
Huang, L. et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat. Med. 21, 1364–1371 (2015).
Google Scholar
Zhou, T. et al. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. J. Exp. Clin. Cancer Res. 42, 111 (2023).
Google Scholar
Gulay, K. C. M. et al. Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res. 83, 3001–3012 (2023).
Google Scholar
Ponz-Sarvise, M. et al. Identification of resistance pathways specific to malignancy using organoid models of pancreatic cancer. Clin. Cancer Res. 25, 6742–6755 (2019).
Google Scholar
Li, Y. et al. Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep. Med. 4, 101162 (2023).
Google Scholar
Jacobetz, M. A. et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62, 112–120 (2013).
Google Scholar
De Jesus-Acosta, A. et al. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Br. J. Cancer 122, 498–505 (2020).
Google Scholar
Van Cutsem, E. et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 38, 3185–3194 (2020).
Google Scholar
Steele, N. G. et al. Inhibition of Hedgehog signaling alters fibroblast composition in pancreatic cancer. Clin. Cancer Res. 27, 2023–2037 (2021).
Google Scholar
Ullman, N. A., Burchard, P. R., Dunne, R. F. & Linehan, D. C. Immunologic strategies in pancreatic cancer: making cold tumors hot. J. Clin. Oncol. 40, 2789–2805 (2022).
Google Scholar
Öhlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017).
Google Scholar
Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102–1123 (2019).
Google Scholar
Biffi, G. et al. IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9, 282–301 (2019).
Google Scholar
Schwörer, S. et al. Hypoxia potentiates the inflammatory fibroblast phenotype promoted by pancreatic cancer cell-derived cytokines. Cancer Res. 83, 1596–1610 (2023).
Google Scholar
Parte, S. et al. Cancer-associated fibroblast induces acinar-to-ductal cell transdifferentiation and pancreatic cancer initiation via LAMA5/ITGA4 axis. Gastroenterology 166, 842–858.e5 (2024).
Google Scholar
Seino, T. et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell 22, 454–467.e6 (2018).
Google Scholar
Choi, J.-I. et al. Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells. Cancer Lett. 498, 42–53 (2021).
Google Scholar
Koikawa, K. et al. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. Cancer Lett. 425, 65–77 (2018).
Google Scholar
Bishehsari, F. et al. KRAS mutation and epithelial-macrophage interplay in pancreatic neoplastic transformation. Int J. Cancer 143, 1994–2007 (2018).
Google Scholar
Holokai, L. et al. Murine- and human-derived autologous organoid/immune cell co-cultures as pre-clinical models of pancreatic ductal adenocarcinoma. Cancers (Basel) 12 (2020).
Meng, Q. et al. Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids. J. Immunother. Cancer 9 (2021).
Lidström, T. et al. Extracellular galectin 4 drives immune evasion and promotes t-cell apoptosis in pancreatic cancer. Cancer Immunol. Res. 11, 72–92 (2023).
Google Scholar
Jiang, S. et al. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance. J. Exp. Clin. Cancer Res. 42, 199 (2023).
Google Scholar
D’Angelo, A., Shibata, K., Tokunaga, M., Furutani-Seiki, M. & Bagby, S. Generation of murine tumour-reactive T cells by co-culturing murine pancreatic cancer organoids and peripheral blood lymphocytes. Biochem. Biophys. Rep. 32, 101365 (2022).
Google Scholar
Zhou, Z. et al. A T cell-engaging tumor organoid platform for pancreatic cancer immunotherapy. Adv. Sci. (Weinh.) 10, e2300548 (2023).
Google Scholar
Knoblauch, M. et al. In-vitro model to mimic T cell subset change in human PDAC organoid co-culture. J. Cancer Res. Clin. Oncol. 149, 13051–13064 (2023).
Google Scholar
Osuna de la Peña, D. et al. Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology. Nat. Commun. 12, 5623 (2021).
Google Scholar
Go, Y.-H. et al. Modeling pancreatic cancer with patient-derived organoids integrating cancer-associated fibroblasts. Cancers (Basel) 14 (2022).
Schuth, S. et al. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. J. Exp. Clin. Cancer Res. 41, 312 (2022).
Google Scholar
Haque, M. R. et al. Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment. Microsyst. Nanoeng. 8, 36 (2022).
Google Scholar
Geyer, M. et al. A microfluidic-based PDAC organoid system reveals the impact of hypoxia in response to treatment. Cell Death Discov. 9, 20 (2023).
Google Scholar
Nakazawa, Y. et al. Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models. Nat. Commun. 15, 2192 (2024).
Google Scholar
Cadavid, J. L. et al. An engineered paper-based 3d coculture model of pancreatic cancer to study the impact of tissue architecture and microenvironmental gradients on cell phenotype. Adv. Health. Mater. 12, e2201846 (2023).
Google Scholar
Lahusen, A. et al. A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing. Sci. Rep. 14, 9377 (2024).
Google Scholar
link